E f f ic i ent ly Com pa ring Bat c h e s o f a n Intac t Mono c lo na l A n t ibo dy using t h e
|
|
- Magdalen Murphy
- 5 years ago
- Views:
Transcription
1 E f f ic i ent ly Com pa ring Bat c h e s o f a n Intac t Mono c lo na l A n t ibo dy using t h e BioPharmaLynx Software Package Scott J. Berger and Weibin Chen Waters Corporation, Milford, MA, U.S.A INTRODUCTION Intact protein LC/MS analysis of a biotherapeutic provides a holistic view with a much simpler set of data than divide and conquer methods such as peptide mapping. The major tradeoffs for intact protein MS analysis are that the types of detectable modifications become more limited as protein mass increases and that modification sites cannot be deduced from the intact mass alone. Assessing clone-to-clone or batch-to-batch variation for glycosylated therapeutic proteins is a common and routine task that often requires significant resources for manual data processing and results integration. When high throughput or rapid sample turnaround is desired, analytical approaches that provide rapid global information about a molecule are preferred over slower approaches that generate more detailed information. For modifications such as oxidized methionines, there is roughly a 16 Da increase over the unmodified protein mass. These modifications can be readily detected at lower levels in the TOF mass spectra of smaller proteins (30 kd and below, e.g. antibody light chains), but require significant stoichiometry to be detected on a 50 kd protein (e.g. antibody heavy chains), and are not readily detectable on large proteins such as a 150 kd intact antibody. For this reason, intact antibody analysis is almost always used in combination with reduced antibody (LC/HC) analysis and peptide mapping studies for fully characterizing batches of a therapeutic antibody. a biotherapeutic. It is also a useful approach for demonstrating the consistency and comparability of individual batches of drug product. Comparative LC/MS analysis of intact antibodies can be accomplished using rapid LC/MS methods. 1-3 Using proper methodology, this type of analysis is robust, and pharmaceutical companies have acquired intact mass data on literally thousands of proteins using OpenLynx enabled open access LC/MS analysis stations. 4-6 The resulting deconvoluted intact mass information found in an OpenLynx report is usually sufficient for routine mass confirmation of a recombinant protein, but often proves limiting for in-depth characterization or comparative profiling studies of biotherapeutics. BiopharmaLynx intact protein analysis workflows are designed to expand functionality for automated batch processing of data by providing additional processing capabilities and related deconvoluted masses to targeted proteins and their variants. In general, there are two classes of protein variants that are typically scrutinized using mass analysis of an intact antibody: glycan structure heterogeneity where variation of core glycans on each heavy chain is extended by a series of 146 to 291 Da carbohydrate units and, the potentially inefficient proteolytic processing of heavy chain carboxy-terminal lysine residues (+128 Da). Assessing this heterogeneity using intact antibody mass profiles can be useful for selecting a clonal expression cell line with desirable product attributes and monitoring the effects of process changes on
2 In addition, the graphical graphical and tabular tools necessary for comparisons of experi mental samples against a gold reference standard are present in the application. This application note discusses key elements of the intact mass workflow, and applies them in the comparative analysis of two batches of a therapeutic monoclonal antibody. Overall, the use of such automated data processing and annotation workflows should allow biopharmaceutical organizations to screen more samples in less time, and make better decisions faster for the development of their biotherapeutic molecules. The LC/MS configuration included an additional post-column desalting valve (system controlled) as detailed in the Care and Use document for the MassPrep Intact Protein Desalting Kit. Acquisition and processing methods The data were acquired using BiopharmaLynx v.1.1, a MassLynx Software application manager that allows laboratories to streamline and automate the processing, bioannotation, and comparison of peptide map and intact protein LC/MS data sets. EXPERIMENTAL LC conditions LC system: Waters nanoacquity UPLC System Column: MassPREP Micro desalting 2.1 x 5 mm Column temp: 65 C Flow rate: 20 µl/min Mobile phase A: Water with 0.1% formic acid Mobile phase B: ACN with 0.1% formic acid Gradient: 10% B for 5 min, 10% B to 90% B over 5 min MS conditions MS system: SYNAPT High Definition Mass Spectrometry (HDMS ) System Ionization mode: ESI+ Capillary voltage: 2.0 kv Cone voltage: 65 V Desolvation temp: 250 C Desolvation gas: 100 L/hr Source temp: 105 C Acquisition range: m/z Calibration range: , CsI, external Sample: 0.5 mg/ml of a monoclonal IgG1 in 25 mm ammonium bicarbonate Sample volume: 3 µl RESULTS AND DISCUSSION Screening of intact antibody variants was accomplished using a simple desalting LC/MS approach. We have previously described 1-3 rapid, reversed-phase desalting methods that use short four-minute cycle times for an intact antibody to facilitate post-column salt diversion during sample loading. Such desalting strategies are advantageous when fast sample turnaround or higher sample throughput is desired. Residual salts on the bound protein were washed away at low organic modifier; rapid gradients were generated to elute proteins as concentrated peaks for mass analysis; and additional sawtooth gradients were applied to ensure that the column was in pristine condition for the subsequent injection. In this work, a variant of this methodology was optimized for the nanoacquity UPLC System, and applied for the analysis of two commercial monoclonal antibody preparations. Automating the data processing and interpretation of two intact antibody desalting runs in BiopharmaLynx was accomplished using spectral summation over the chromatographic elution profile of the antibody, subjecting the summed spectrum to MaxEnt 1 spectral deconvolution, and searching the resulting deconvoluted masses against the antibody sequence and a series of common biantennary glycan modifications. The following sections will describe this processing workflow in greater detail.
3 Our standard approach for processing very large proteins, such as intact antibodies, is to deconvolute a selected high signal-to-noise m/z range within the summed mass spectrum. This heartcut m/z region (typically comprising at least six charge states) contains the best population of peaks with good signal-to-noise that are not artificially broadened by the presence of adducts, (which is an issue at higher m/z). These higher m/z peaks, (fewer charges) represent more folded structures that can preferentially maintain neutral and salt adduct associations during the electrospray process. Our method (Figure 1) specifies the spectral deconvolution of peaks between 2500 and 3000 m/z in the raw data summed between 10 and 12 minutes to produce a MaxEnt1 zero-charge-state deconvolution spectrum in the range of 147,000 to 150,000 Da. This selected retention window and mass range are highlighted by shaded regions on the mirrored differential plots of the total ion chromatogram (Figure 2) and summed raw mass spectra (Figure 3A). Enlarging several charge-states within this region (Figure 3B) shows the complex nature of each charge-state arising from the various glycovariants of the antibody, while the differential plot shows consistent relative intensity differences of individual glycovariants across charge-states. From this repeating pattern of differential intensity, it would be expected that the final deconvoluted result would reflect a similar pattern of relative glycovariant intensity differences between the two samples. Additional settings for MaxEnt1 deconvolution of the antibody data are accessible through the advanced deconvolution settings button (Figure 1, red box highlight). These settings (Figure 4) show that the summed spectrum was background subtracted prior to applying 15 cycles of MaxEnt1 spectral deconvolution, and that the MaxEnt1 deconvoluted spectrum was background subtracted prior to measuring the height centroid of each peak. It is these centroid mass-intensity values that populate the results table and that are used for annotating protein variant structures. Figure 1. BiopharmaLynx Method Editor screen detailing protein search, spectral summation, and spectral deconvolution parameters. BiopharmaLynx allows users to custom define time regions within an LC/MS run, associate each of those regions with optimal spectral deconvolution conditions, and target proteins for annotation against the observed masses. Figure 2. Results Browser differential Total Ion Chromatogram mirror plot for two intact antibody LC/MS analysis runs.
4 3A 3B 3B Figure 3. Results Browser differential Raw Mass Spectrum mirror plots for two intact antibody LC/MS analysis runs. The m/z region, processed to produce the deconvoluted spectra, is shaded in the full range display (Figure 3A). A zoomed-in region of m/z (Figure 3B) shows systematic glycovariant relative intensity differences (purple trace) across several charge states. Figure 4. BiopharmaLynx Method screen detailing advanced deconvolution parameters.
5 BiopharmaLynx contains the latest generation MaxEnt1 spectral deconvolution algorithm. While a full discussion of this improved algorithm will appear in a separate technical note, it is important to focus on several settings (Figure 4) selected for processing of the antibody LC/MS data. First, the automated peak width function is not selected. This new capability automatically populates the MaxEnt1 spectral peak width setting based on the entered instrument resolution and average output mass range. This width value can be modeled effectively for smaller proteins (under 40 kd) that do not have significant charge-state peak broadening due to adducts or micro-heterogeneity. However, the width value cannot be modeled effectively for larger proteins due to the greater occurrence and magnitude of these effects. In both the automated and manual peak width modes, the improved MaxEnt1 algorithm now better models TOF instrument data by recognizing that peak width on TOF instruments systematically varies with m/z. Thus, two spectral peak width settings (typically measured for the best resolved or most intense variant at half peak height) that correspond to the highest (low m/z) and lowest (high m/z) charge-states used for deconvolution can be entered in the manual mode. For the two antibody data sets, these values were determined as 1.7 and 2.0, respectively. Selecting a common value for both entries would mirror what is implemented in the current MassLynx Software v.4.1 implementation of MaxEnt1, when the Uniform Gaussian peak width model is used. This method applies 15 iterations of MaxEnt1 processing to the data rather than taking the deconvolution process to full convergence of the mass spectral and model ( mock )-spectral data sets. This choice is made in recognition that the peak models used by MaxEnt, even with variable spectral peak width, cannot perfectly match data for large proteins (>100 kd). There is unresolved microheterogeneity within each charge-state, and adducts preferentially interact with lower charge-state/structures of a protein. Both effects produce additional variance in peak width and peak asymmetry that are not directly predictable. This unaccounted-for spectral signal can contribute to additional peak structure in the deconvoluted spectrum, which is not evidenced within the raw spectral data, and which typically begins to appear in later MaxEnt1 iterations. The improved TOF model has reduced the occurrence and magnitude of such peaks, but they may still be generated during large protein deconvolution studies. Selecting the number of iterations provides proper resolution and relative quantitation of protein variants, while avoiding these potential artifacts, is an important part of developing a robust data processing workflow for large proteins. The proper balance can be achieved for biotherapeutic antibody analysis, as indicated by the recent published work of Gadgil and colleagues. 8
6 The resulting deconvoluted spectrum produced by MaxEnt1 processing of the two data sets (Figure 5) displays systematic differences between antibody samples. Consistent with the raw spectra differential display (Figure 3B), the lower sample is enriched with higher mass glycovariants and deficient in some lower mass glycovariants. As a simple validation exercise, true differences between deconvoluted protein spectra should be observable in the underlying raw charge-state data, although these differences can be subtle. Additional information about a selected peak in the deconvoluted data (corresponding to the G0F/G1F glycoform) was obtained by mouse-over at the peak apex. The centroided mass-intensity information derived from this deconvoluted spectrum was used to produce tabular results and processed spectra/chromatogram views (not shown) of the data. Figure 5. Results Browser differential MaxEnt1 deconvoluted mass spectrum mirror plots for two intact antibody LC/MS analysis runs. The glycovariant intensity differences apparent in the raw data are also evident in the differential deconvoluted spectrum (purple line).
7 Figure 6. BiopharmaLynx Method bond screens detailing antibody sequence and disulfide information for targeted search against the deconvoluted mass results. The bioinformatic assignment of antibody masses to protein structures was also accomplished as part of the processing method. The recombinant IgG1 antibody sequence was defined in the method (Figure 6) as a single protein with four protein chains (two heavy, two light) containing 16 intermolecular and intramolecular disulfide bonds. The sequence has been randomized to obscure the identity of the biotherapeutic molecule used in this comparative analysis. Defining the correct number of disulfide linkages is important, as each disulfide will increment the predicted protein mass downwards by 2 Da, or roughly a -32 Da mass difference for the intact antibody.
8 Modifications searched in the method (Figure 7) included a set of seven common biantennary glycan structures targeted to canonical NX(S/T) N-glycosylation sites (e.g. G0F in Figure 7, inset). Figure 7. BiopharmaLynx Method screen detailing modifications considered during the protein search. Note that Glycosylation modifications are searched with NX(S/T) sequence specificity, and users can limit the maximum number of a modification that can be present on a protein.
9 The peak match data table (Figure 8) links the processed data to the proteins and modifications assigned through a targeted bioinformatic search. Shown are the top 10 most intense components identified in the control sample, sorted from the most to least intense. Figure 8. Results Browser Tabular Results View (Focus on control sample results) shows that the Top 10 most intense peaks correspond to glycovariants of the searched antibody. The green color of each row indicates that the variant was observed in both the control and experimental analyte samples. Relative levels of a variant within a sample are seen in the (%Total) column, while differences between the samples are displayed in additional columns in the table (not shown). The table also contains information about the detection of these components in the analyte, and mass/intensity differences between the two samples (not shown for figure legibility). All 10 components were assigned to antibody glycovariants structures, and the green shaded row indicates that the components were all detected within the deconvolution results generated for both samples. n BiopharmaLynx results are protein-centric. The peak-match PROCESSED RESULTS data table links the processed data to proteins and modifications found in a targeted bioinformatic search. n These annotated data interactively supply information for the Targeted protein and modification search various viewing tools that enable effective data analysis. n A software user can select between alternative annotations CHROMATOGRAM VIEWS ANNOTATED PEAK MATCH DATA TABLE USER KNOWLEDGE produced by the search, or use their knowledge to manually annotate data table results. n All data views are sensitive to changes in the data table and are updated with these changes. The control intensity (% Total) value is linked to the selection column SPECTRUM VIEWS to its right, and generates on-the-fly calculations of relative composition of the selected components within an individual sample. Figure 9. The overall BiopharmaLynx results workflow is component- and protein-centric. The peak match data table links the processed data (detected components with an RT, mass, intensity) to proteins and associated modifications found through the targeted bioinformatic search. These bioinformatics-assigned annotations can be revised by the user, and such changes will be propagated throughout the chromatogram/spectral viewing and reporting tools.
10 This peak-match data table represents a central location for processed data that supplies annotation information to the various tools that facilitate graphical result viewing and sample-sample comparisons. As depicted in Figure 9, a central BiopharmaLynx paradigm is that scientists are the ultimate arbiters for interpreting results generated by the program. This may include aligning and normalizing data, altering minimum intensity thresholds for peak detection, adjusting incorrect assignments produced by a search, choosing between alternative assignments fitting the protein search criteria, or using their knowledge to manually annotate components within a sample. Chromatographic and spectral displays are immediately updated with any changes to annotations, and user-comments associated with individual components can be included when constructing reporting templates. the processing and synthesis of useful information from the abundance of raw data generated by these studies. The BiopharmaLynx Application Manager has been designed to address this productivity limitation by automating processing and bioannotation of such data, while providing tools for sample comparison, data export, and report generation. Overall, these improved workflow efficiencies facilitate the rapid communication of results to other scientists and organizations, and help these groups make better decisions faster about the development of their biotherapeutics. References 1. Rapid Profiling of Monoclonal Intact Antibodies by LC/ESI-TOF MS. Waters Application Note, 2007; en. 2. Rapid Screening of Reduced Monoclonal Antibodies by LC/ESI-TOF MS. Waters Application Note, 2007; en. 3. Characterization of an IgG1 monoclonal antibody and related sub-structures by LC/ ESI-TOF MS. Waters Application Note, 2007; en. CONCLUSIONS This application note has detailed how the BiopharmaLynx Application Manager can demonstrate batch-to-batch differences in the glycovariant profile of a recombinant therapeutic monoclonal antibody. Important points in this note cover many of the best practices we employ to build processing methods capable of recognizing and comparing LC/TOF-MS profiles of therapeutic antibody variants, and a rational framework for assessing that deconvolution conditions have been properly selected. Today, LC/MS data on intact antibodies can be routinely collected using fast and robust analytical methodologies. The productivity-limiting step for many analytical groups has become 4. Analyzing More Protein Samples with the Same Headcount: Is Open Access LC/MS Part of a Solution for Increasing Throughput While Decreasing Analysis Turnaround Time? Poster presented at the Mass Spec Meeting, 2007; en. 5. Assessing the Quality and Precision of Therapeutic Antibody LC/MS Data Acquired and Processed using Automated Workflows, Poster presented at the ASMS Meeting. 2008; en. 6. White WL, Wagner CD, Hall JT, Chaney EE, George B, Hofmann K, Miller LA, Williams JD. Protein Open-access Liquid Chromatography/Mass Spectrometry. Rapid Commun Mass Spectrom, 2005; 19(2): Wagner CD, Hall JT, White WL, Miller LA, Williams JD. Automated Mass Correction and Data Interpretation for Protein Open-access Liquid Chromatography-mass Spectrometry. J Mass Spectrom, 2007; 42(2): Gadgil HS, Pipes GD, Dillon TM, Treuheit MJ, Bondarenko PV. Improving Mass Accuracy of High Performance Liquid Chromatography/electrospray Ionization Time-of-flight Mass Spectrometry of Intact Antibodies. J Am Soc Mass Spectrom, 2007; 17(6): Waters and nanoacquity UPLC, are registered trademarks of Waters Corporation. OpenLynx, MassLynx, BiopharmaLynx, MaxEnt, MassPREP, SYNAPT, High Definition Mass Spectrometry, HDMS, and The Science of What s Possible are trademarks of Waters Corporation Waters Corporation. Produced in the U.S.A. November en AG-PDF Waters Corporation 34 Maple Street Milford, MA U.S.A. T: F:
Generating Automated and Efficient LC/MS Peptide Mapping Results with the Biopharmaceutical Platform Solution with UNIFI
with the Biopharmaceutical Platform Solution with UNIFI Vera B. Ivleva, Ying Qing Yu, Scott Berger, and Weibin Chen Waters Corporation, Milford, MA, USA A P P L I C AT ION B E N E F I T S The ability to
More informationProteins. Patrick Boyce Biopharmaceutical Marketing Manager Waters Corporation 1
Routine Characterization of mabs and Other Proteins Patrick Boyce Biopharmaceutical Marketing Manager Europe and India 2011 Waters Corporation 1 Agenda Why? What scientific challenges? Technology Example
More informationAsish Chakraborty, St John Skilton, Weibin Chen and John C. Gebler Waters Corporation, Milford, MA, U.S. INTRODUCTION METHODS. Sample preparation
Com p r e h ensiv e a n d Rou t in e C ha r ac t e riz at io n o f P rot eins a n d P e p t i d e s by LC/MS and LC/MS E Asish Chakraborty, St John Skilton, Weibin Chen and John C. Gebler Waters Corporation,
More informationMaximizing Chromatographic Resolution of Peptide Maps using UPLC with Tandem Columns
Maximizing Chromatographic Resolution of Peptide Maps using UPLC with Tandem Columns Hongwei Xie, Martin Gilar, and Jeff Mazzeo Waters Corporation, Milford, MA U.S. APPLICATION BENEFITS The ACQUITY UPLC
More informationPrecise Characterization of Intact Monoclonal Antibodies by the Agilent 6545XT AdvanceBio LC/Q-TOF
Precise Characterization of Intact Monoclonal Antibodies by the Agilent 6545XT AdvanceBio LC/Q-TOF Application Note Author David L. Wong Agilent Technologies, Inc. Santa Clara, CA, USA Introduction Monoclonal
More informationEoin F.J. Cosgrave, Matthew A. Lauber, Robert Birdsall, and Sean M. McCarthy Waters Corporation, Milford, MA, USA APPLICATION BENEFITS INTRODUCTION
New Capabilities for Monitoring Released N-Glycans through the Combined Use of RapiFluor-MS Labeling, ACQUITY UPLC H-Class Bio System, and Serial Fluorescence/ACQUITY QDa Mass Detection Eoin F.J. Cosgrave,
More informationSeparation of Native Monoclonal Antibodies and Identification of Charge Variants:
Separation of Native Monoclonal Antibodies and Identification of Charge Variants: Teamwork of the Agilent 31 OFFGEL Fractionator, Agilent 21 Bioanalyzer and Agilent LC/MS Systems Application Note Biosimilar
More informationMethod Development Considerations for Reversed-Phase Protein Separations
Method Development Considerations for Reversed-Phase Protein Separations Hillary B. Hewitson, Thomas E. Wheat, Paula Hong, Kenneth J. Fountain APPLICATION BENEFITS n The BEH00 C 4 chemistry is available
More informationAnalysis of Monoclonal Antibody (mab) Using Agilent 1290 Infinity LC System Coupled to Agilent 6530 Accurate-Mass Quadrupole Time-of-Flight (Q-TOF)
Analysis of Monoclonal Antibody (mab) Using Agilent 9 Infinity LC System Coupled to Agilent Accurate-Mass Quadrupole Time-of-Flight (Q-TOF) Application Note Authors Ravindra Gudihal and Suresh Babu CV
More informationProfiling Glycosylation of Monoclonal Antibodies at Three Levels Using the Agilent 6545XT AdvanceBio LC/Q TOF
Application Note Biotherapeutics and Biosimilars Profiling Glycosylation of Monoclonal Antibodies at Three Levels Using the Agilent 64XT AdvanceBio LC/Q TOF Author David L. Wong Agilent Technologies, Inc.
More informationMassPREP On-Line Desalting Cartridge
CONTENTS I. INTRODUCTION II. INSTALLING THE MASSPREP ON-LINE DESALTING CARTRIDGE INTO THE SENTRY.1 X 1 MM GUARD COLUMN HOLDER III. RECOMMENDED LC/MS SYSTEM CONFIGURATION TO MINIMIZE MS SOURCE CONTAMINATION
More informationApplication Note # ET-20 BioPharma Compass: A fully Automated Solution for Characterization and QC of Intact and Digested Proteins
Application Note # ET-20 BioPharma Compass: A fully Automated Solution for Characterization and QC of Intact and Digested Proteins BioPharma Compass TM is a fully automated solution for the rapid characterization
More informationCharacterization of a fusion protein under native and denaturing conditions with maxis II
Characterization of a fusion protein under native and denaturing conditions with maxis II Abstract The maxis II UHR-QTOF was used to characterize key attributes of a fusion protein in its native conformation
More informationPLRP-S Polymeric Reversed-Phase Column for LC/MS Separation of mabs and ADC
PLRP-S Polymeric Reversed-Phase Column for LC/MS Separation of mabs and ADC Analysis of Intact and Fragmented mabs and ADC Application Note Biotherapeutics and Biologics Author Suresh Babu C.V. Agilent
More informationADVANCING ATTRIBUTE CONTROL OF ANTIBODIES AND ITS DERIVATIVES USING HIGH RESOLUTION ANALYTICS
ADVANCING ATTRIBUTE CONTROL OF ANTIBODIES AND ITS DERIVATIVES USING HIGH RESOLUTION ANALYTICS Henry Shion 1, Jing Fang 1, William Alley 1, Barbara Sullivan 2, Nick Tomczyk 3, Liuxi Chen 1, Ying-Qing Yu
More informationCharacterization of intact monoclonal antibody with microfluidic chip electrophoresis mass spectrometry
POSTER NOTE 65 Characterization of intact monoclonal antibody with microfluidic chip electrophoresis mass spectrometry Authors Chien-Hsun Chen, 1 Andreas Krupke, 2 Stephane Houel, 1 Aaron Bailey, 1 Aran
More informationMulti-Enzyme Digestion for Biotherapeutic Peptide Mapping: Examining BiopharmaLynx 1.3 Functionality
Multi-Enzyme Digestion for Biotherapeutic Peptide Mapping: Examining BiopharmaLynx 1.3 Functionality Scott J. Berger Waters Corporation, Milford, MA, USA TECHNOLOGY BENEFITS Enabling advanced multi-protease
More informationBIOPHARMACEUTICAL. Key Applications PLATFORM SOLUTION
BIOPHARMACEUTICAL Key Applications PLATFORM SOLUTION TABLE OF CONTENTS Biopharmaceutical Platform Solution with UNIFI: Key Applications Intact Protein MS Analysis I Peptide Mapping I Released Glycan Analysis
More informationMonoclonal Antibody Characterization on Q Exactive and Oribtrap Elite. Yi Zhang, Ph.D Senior Proteomic Marketing Specialist Oct.
Monoclonal Antibody Characterization on Q Exactive and Oribtrap Elite Yi Zhang, Ph.D Senior Proteomic Marketing Specialist Oct. 12, 211 Outline Orbitrap Mass Spectrometer in mab Characterization Intact
More informationApplication of Agilent AdvanceBio Desalting-RP Cartridges for LC/MS Analysis of mabs A One- and Two-dimensional LC/MS Study
Application of Agilent AdvanceBio Desalting-RP Cartridges for LC/MS Analysis of mabs A One- and Two-dimensional LC/MS Study Application note Biotherapeutics and Biologics Authors Suresh Babu C.V., Anne
More informationTabisam Khan 1, David R. Little 1, Liyu Yang 2, Jiwen Chen 2, Parya Nouri 2, Samy Tadros 2, Patrick J. Rudewicz 2
AIMS High throughput bioanalysis plays a central role in the drug discovery and development process. The resulting data are used to determine a drug candidate's pharmacokinetic parameters that are crucial
More informationXevo G2-S QTof and TransOmics: A Multi-Omics System for the Differential LC/MS Analysis of Proteins, Metabolites, and Lipids
Xevo G2-S QTof and TransOmics: A Multi-Omics System for the Differential LC/MS Analysis of Proteins, Metabolites, and Lipids Ian Edwards, Jayne Kirk, and Joanne Williams Waters Corporation, Manchester,
More informationProMass HR Applications!
ProMass HR Applications! ProMass HR Features Ø ProMass HR includes features for high resolution data processing. Ø ProMass HR includes the standard ProMass deconvolution algorithm as well as the full Positive
More informationDeveloping Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus
Developing Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus Robert Birdsall, Thomas Wheat, and Weibin Chen Waters Corporation,
More informationBiotherapeutic Non-Reduced Peptide Mapping
Biotherapeutic Non-Reduced Peptide Mapping Routine non-reduced peptide mapping of biotherapeutics on the X500B QTOF System Method details for the routine non-reduced peptide mapping of a biotherapeutic
More informationSimple, Robust, High Quality Intact Mass Analysis A Biosimilars Case Study
3 Conjugation Site (ADC) 4 34 35 1 1 35 34 CASE STUDY 3 National Institute for Bioprocessing 3 4 Research and Training 1 35 31 5 31 3 6 9 3 9 5 6 7 7 6 8 8 3 1 19 16 17 19 18 7 9 11 11 5 17 9 7 3 1 9 9
More informationEnsure your Success with Agilent s Biopharma Workflows
Ensure your Success with Agilent s Biopharma Workflows Steve Madden Software Product Manager Agilent Technologies, Inc. June 5, 2018 Agenda Agilent BioPharma Workflow Platform for LC/MS Intact Proteins
More informationAnalysis of Intact Monoclonal Antibodies Using an M3 MicroLC with the TripleTOF 6600
Procedures Analysis of Intact Monoclonal Antibodies Using an M3 MicroLC with the TripleTOF 66 Robust and Sensitive Workflow for Qualitative and Quantitative Analysis of Biotherapeutic IgGs Khatereh Motamedchaboki,
More informationUnified Workflow for Monoclonal Antibody Charge Heterogeneity, Purity, and Molecular Weight Analysis
Procedures Unified Workflow for Monoclonal Antibody Charge Heterogeneity, Purity, and Molecular Weight Analysis Separation and Online Detection of Intact mab Variants and Impurities using CESI-MS Bryan
More informationApplication Note LCMS-87 Automated Acquisition and Analysis of Data for Monitoring Protein Conjugation by LC-MS Using BioPharma Compass
Application Note LCMS-87 Automated Acquisition and Analysis of Data for Monitoring Protein Conjugation by LC-MS Using BioPharma Compass Abstract Here we describe the development and use of an automated
More informationClone Selection Using the Agilent 1290 Infinity Online 2D-LC/MS Solution
Clone Selection Using the Agilent 9 Infinity Online D-LC/MS Solution Application Note Biopharmaceuticals Authors Abstract Ravindra Gudihal and This Application Note describes the Agilent 9 Infinity online
More informationA Highly Accurate Mass Profiling Approach to Protein Biomarker Discovery Using HPLC-Chip/ MS-Enabled ESI-TOF MS
Application Note PROTEOMICS METABOLOMICS GENOMICS INFORMATICS GLYILEVALCYSGLUGLNALASERLEUASPARG CYSVALLYSPROLYSPHETYRTHRLEUHISLYS A Highly Accurate Mass Profiling Approach to Protein Biomarker Discovery
More informationOverview of Waters Solutions for Biopharmaceutical Analysis and Characterization
Overview of Waters Solutions for Biopharmaceutical Analysis and Characterization Denis Calnan Biopharma Business Development Manager (Northern Europe) 2011 Waters Corporation 1 About Waters Facts and Figures
More informationAnswers, Simple and Streamlined. Solutions for Biotherapeutic Intact Mass Analysis
Answers, Simple and Streamlined Solutions for Biotherapeutic Intact Mass Analysis Expert Functionality for Mass Spec Non-Experts SCIEX OS on the X500B QTOF system dramatically improves the user experience,
More informationTrastuzumab Glycan Batch-to-Batch Profiling using a UPLC/FLR/Mass Spectrometry Platform
Trastuzumab Glycan Batch-to-Batch Profiling using a UPLC/FLR/Mass Spectrometry Platform Ying Qing Yu, Joomi Ahn, and Martin Gilar Waters Corporation, Milford, MA, U.S. APPLICATION BENEFITS Used together,
More informationIsotopic Resolution of Chromatographically Separated IdeS Subunits Using the X500B QTOF System
Isotopic Resolution of Chromatographically Separated IdeS Subunits Using the X500B QTOF System Fan Zhang 2, Sean McCarthy 1 1 SCIEX, MA, USA, 2 SCIEX, CA USA Analysis of protein subunits using high resolution
More informationMass Spectrometry Analysis of Liquid Chromatography Fractions using Ettan LC MS System
GUIDE TO LC MS - December 21 1 Spectrometry Analysis of Liquid Chromatography Fractions using Ettan LC MS System Henrik Wadensten, Inger Salomonsson, Staffan Lindqvist, Staffan Renlund, Amersham Biosciences,
More informationAnalysis of Monoclonal Antibodies and Their Fragments by Size Exclusion Chromatography Coupled with an Orbitrap Mass Spectrometer
Analysis of Monoclonal Antibodies and Their Fragments by Size Exclusion Chromatography Coupled with an Orbitrap Mass Spectrometer Shanhua Lin, 1 Hongxia Wang, 2 Zhiqi Hao, 2 Patrick Bennett, 2 and Xiaodong
More informationFast and Efficient Peptide Mapping of a Monoclonal Antibody (mab): UHPLC Performance with Superficially Porous Particles
Fast and Efficient Peptide Mapping of a Monoclonal Antibody (mab): UHPLC Performance with Superficially Porous Particles Application Note Biotherapeutics and Biosimilars Authors James Martosella, Alex
More informationApplication Note. Authors. Abstract. Ravindra Gudihal Agilent Technologies India Pvt. Ltd. Bangalore, India
Quantitation of Oxidation Sites on a Monoclonal Antibody Using an Agilent 1260 Infinity HPLC-Chip/MS System Coupled to an Accurate-Mass 6520 Q-TOF LC/MS Application Note Authors Ravindra Gudihal Agilent
More informationPut the PRO in Protein Characterization
Put the PRO in Protein Characterization Aaron Boice LC/Q-TOF Product Manager 5-June-2017 Agenda The Right Tools for the Job Tackling Intact Proteins Break it Down Peptides and PTMs Sweet Success Released
More informationCharacterization of Glycosylation in the Fc Region of Therapeutic Recombinant Monoclonal Antibody
Characterization of Glycosylation in the Fc Region of Therapeutic Recombinant Monoclonal Antibody Application Note BioPharma Authors James Martosella, Phu Duong, and Alex Zhu Agilent Technologies, Inc.
More informationRapid Peptide Catabolite ID using the SCIEX Routine Biotransform Solution
Rapid Peptide Catabolite ID using the SCIEX Routine Biotransform Solution Rapidly Identify Major Catabolites with the SCIEX X500R QTOF System and MetabolitePilot TM 2.0 Software Ian Moore and Jinal Patel
More informationThermo Scientific Solutions for Intact-Protein Analysis. Better, Faster Decisions for. Biotherapeutic Development
Thermo Scientific Solutions for Intact-Protein Analysis Better, Faster Decisions for Biotherapeutic Development Quickly and Accurately Assess Product Quality and Safety Therapeutic proteins and monoclonal
More informationApplication Note. Author. Abstract. Biotherapeutics and Biologics. Sonja Schneider Agilent Technologies, Inc. Waldbronn, Germany
D-LC/MS Characterization of Charge Variants Using Ion Exchange and Reversed-Phase Chromatography Multiple Heart-Cutting D-LC Analysis of Innovator versus Biosimilar Monoclonal Antibodies Application Note
More informationof peptide mapping chemistries, 130Å or 300Å with tunable UV, photodiode array, or mass spectrometry
UPLC PEPTIDE ANALYSIS SOLUTION UPLC Peptide Analysis Solution: n ACQUITY UPLC System n Peptide Separation Technology chemistries, 130Å or 300Å n Flexible detection capabilities, with tunable UV, photodiode
More informationHighly Confident Peptide Mapping of Protein Digests Using Agilent LC/Q TOFs
Technical Overview Highly Confident Peptide Mapping of Protein Digests Using Agilent LC/Q TOFs Authors Stephen Madden, Crystal Cody, and Jungkap Park Agilent Technologies, Inc. Santa Clara, California,
More informationAdvanced Characterization of Antibody Drug Conjugates (ADCs) by Liquid Chromatography and Mass Spectrometry (LC/MS) John Gebler, Ph.D.
Advanced Characterization of Antibody Drug Conjugates (ADCs) by Liquid Chromatography and Mass Spectrometry (LC/MS) John Gebler, Ph.D. Director www.waters.com/adc 2015 Waters Corporation 1 2015 Waters
More informationA Unique LC-MS Assay for Host Cell Proteins(HCPs) ) in Biologics
A Unique LC-MS Assay for Host Cell Proteins(HCPs) ) in Biologics Catalin Doneanu,, Ph.D. Biopharmaceutical Sciences, Waters September 16, 2009 Mass Spec 2009 2009 Waters Corporation Host Cell Proteins
More informationMassHunter Profinder: Batch Processing Software for High Quality Feature Extraction of Mass Spectrometry Data
MassHunter Profinder: Batch Processing Software for High Quality Feature Extraction of Mass Spectrometry Data Technical Overview Introduction LC/MS metabolomics workflows typically involve the following
More informationBiotherapeutic Peptide Mapping Information Dependent Acquisition (IDA) Method
Biotherapeutic Peptide Mapping Information Dependent Acquisition (IDA) Method Routine biotherapeutic accurate mass peptide mapping analysis on the X500B QTOF System Method details for the routine peptide
More informationSolutions for the Core and Protein Laboratory: MassHunter Walkup
Solutions for the Core and Protein Laboratory: MassHunter Walkup Jade C. Byrd MS Software Product Manager Page 1 Common Challenges in Characterizing Biomolecules Molecular size (insulin is 5 kda, mabs
More informationExploring Extra Sensitivity Using ionkey/ms with the Xevo G2-XS Q-Tof HRMS for Small Molecule Pharmaceutical Analysis in Human Plasma
Exploring Extra Sensitivity Using ionkey/ms with the Xevo G2-XS Q-Tof HRMS for Small Molecule Pharmaceutical Analysis in Human Plasma Yun Wang Alelyunas, Mark D. Wrona, Jim Murphy, Angela Doneanu, Gregory
More informationCharacterize Fab and Fc Fragments by Cation-Exchange Chromatography
Characterize Fab and Fc Fragments by Cation-Exchange Chromatography Application Note Biologics and Biosimilars Authors Isabel Vandenheede, Emmie Dumont, Pat Sandra, and Koen Sandra Research Institute for
More informationA Complete Workflow Solution for Intact Monoclonal Antibody Characterization Using a New High-Performance Benchtop Quadrupole- Orbitrap LC-MS/MS
A Complete Workflow Solution for Intact Monoclonal Antibody Characterization Using a New High-Performance Benchtop Quadrupole- Orbitrap LC-MS/MS Zhiqi Hao, 1 Yi Zhang, 1 David Horn, 1 Seema Sharma, 1 Shiaw-Lin
More informationHigh-resolution Analysis of Charge Heterogeneity in Monoclonal Antibodies Using ph-gradient Cation Exchange Chromatography
High-resolution Analysis of Charge Heterogeneity in Monoclonal Antibodies Using ph-gradient Cation Exchange Chromatography Agilent 1260 Infinity Bio-inert Quaternary LC System with Agilent Bio Columns
More informationChromatography column for therapeutic protein analysis
PRODUCT SPECIFICATIONS ProPac Elite WCX Column Chromatography column for therapeutic protein analysis Benefits Superior resolution power for proteins, monoclonal antibodies, and associated charge variants
More information2012 Waters Corporation 1
UPLC User meeeting April 2012 Principles and Practices for SEC, IEX for Intact Protein Analysis by UPLC anders_feldthus@waters.com 2012 Waters Corporation 1 Agenda Ion-Exchange Chromatography Theory and
More informationQUANLYNX APPLICATION MANAGER
QUANLYNX APPLICATION MANAGER OVERVIEW INTRODUCTION QuanLynx, an Application Manager included with Waters MassLynx Software, is designed for quantitative analysis. Simply acquiring mass spectrometry data
More informationENHANCED PROTEIN AND PEPTIDE CHARACTERIZATION
Agilent MassHunter BioConfirm Software ENHANCED PROTEIN AND PEPTIDE CHARACTERIZATION Spectrum Algorithm Peak Modeling Deconvolution Mass 16951.778 Sequence Name Myoglobin (horse) Target mass 16951.673
More informationLC/MS Based Quantitation of Intact Proteins for Bioanalytical Applications
LC/MS Based Quantitation of Intact Proteins for Bioanalytical Applications Alex Zhu, Ph.D. Agilent Technologies Wilmington, DE ASMS,2017-06 1 Outline Introduction on intact protein quantitation Agilent
More informationThermo Scientific Peptide Mapping Workflows. Upgrade Your Maps. Fast, confident and more reliable peptide mapping.
Thermo Scientific Peptide Mapping Workflows Upgrade Your Maps Fast, confident and more reliable peptide mapping. Smarter Navigation... Peptide mapping is a core analytic in biotherapeutic development.
More informationBIOANALYTICAL STRATEGY FOR IN VITRO METABOLITE SCREENING WITH EXACT MASS USING THE Q-Tof micro. Jose M. Castro-Perez 1, Carina Leandersson 2
In metabolism studies, it is vital to understand how a particular drug is absorbed, distributed, metabolised, and eliminated by the body. Metabolite identification is a very important part of the drug
More informationEnabling routine characterization of proteins. Agilent MassHunter BioConfirm software
Enabling routine characterization of proteins Agilent MassHunter BioConfirm software Bioconfirm a key component of your major biopharma workflows Intact protein analysis BioConfirm will rapidly deconvolute
More informationAntibody Analysis by ESI-TOF LC/MS
Application Note PROTEOMICS METABOLOMICS GENOMICS INFORMATICS GLYILEVALCYSGLUGLNALASERLEUASPARG CYSVALLYSPROLYSPHETYRTHRLEUHISLYS Antibody Analysis by ESI-TOF LC/MS Authors Lorenzo Chen, Merck & Company,
More informationMonoclonal Antibody Analysis on a Reversed-Phase C4 Polymer Monolith Column
Monoclonal Antibody Analysis on a Reversed-Phase C4 Polymer Monolith Column Shane Bechler 1, Ken Cook 2, and Kelly Flook 1 1 Thermo Fisher Scientific, Sunnyvale, CA, USA; 2 Thermo Fisher Scientific, Runcorn,
More informationUNIFI: an innovative enabling platform Ken Eglinton Nordic User Training, September 2013
UNIFI: an innovative enabling platform Ken Eglinton Nordic User Training, September 2013 2013 Waters Corporation 1 Waters Laboratory Informatics Product Portfolio MassLynx Mass Spectrometry Software NuGenesis
More informationStreamlined and Complete LC-MS Workflow for MAM
Streamlined and Complete LC-MS Workflow for MAM Multiple Attribute Methodology (MAM) for Biotherapeutic Attribute Monitoring and Purity Testing BV MAM WORKFLOW Define Track Quantify Purity New Peaks Report
More informationCell Clone Selection Using the Agilent Bio-Monolith Protein A Column and LC/MS
Cell Clone Selection Using the Agilent Bio-Monolith Protein A Column and LC/MS Application Note Biopharmaceuticals and Biosimilars Authors Emmie Dumont, Isabel Vandenheede, Pat Sandra, Koen Sandra Research
More informationDisulfide Linkage Analysis of IgG1 using an Agilent 1260 Infinity Bio inert LC System with an Agilent ZORBAX RRHD Diphenyl sub 2 µm Column
Disulfide Linkage Analysis of IgG1 using an Agilent 126 Infinity Bio inert LC System with an Agilent ZORBAX RRHD Diphenyl sub 2 µm Column Application Note Biotherapeutics & Biosimilars Author M. Sundaram
More informationA Comprehensive Approach for Monoclonal Antibody N-linked Glycan Analysis from Sample Preparation to Data Analysis
Application ote Biotherapeutics and Biosimilars A Comprehensive Approach for Monoclonal Antibody -linked Glycan Analysis from Sample Preparation to Data Analysis Authors David L. Wong, scar Potter, Jordy
More informationHDX-MS at Waters Waters Corporation 1
HDX-MS at Waters 2011 Waters Corporation 1 Hydrogen Deuterium Exchange MS systems Dedicated standards and UPLC BEH separation chemistries nanoacquity UPLC with HDX technology Xevo G2-S QTof MS and Synapt
More informationIllicit Drug Analysis in Urine Using 2D LC-MS/MS for Forensic Toxicology
Claude Mallet 1 and Sabra Botch-Jones 2 1 Waters Corporation, Milford, MA, USA 2 Boston University School of Medicine, Boston, MA, USA APPLICATION BENEFITS Fast extraction protocol (2 min) 1 ppt detection
More informationN-Glycan Profiling Analysis of a Monoclonal Antibody Using UHPLC/FLD/Q-TOF
N-Glycan Profiling Analysis of a Monoclonal Antibody Using UHPLC/FLD/Q-TOF Application Note Authors Xianming Liu, Wei Zhang, Yi Du, Sheng Yin, Hong Que, and Weichang Zhou WuXi AppTec iopharmaceuticals
More informationZipChip TM. Microfluidic CE-ESI Biotherapeutics CE-ESI-MS Applications. Please visit us at
ZipChip TM Microfluidic CE-ESI Biotherapeutics CE-ESI-MS Applications Please visit us at http://www.908devices.com/ // Actionable Intelligence HPMS & On-board Analytics / Slide 1 June 2016 // ZipChip CE-ESI
More informationA comprehensive CE/ESI-MS solution for BioPharma applications
A comprehensive CE/ESI-MS solution for BioPharma applications Thermo Scientific Q Exactive hybrid quadrupole-orbitrap mass spectrometers with ZipChip system Fast CE Separation Nanospray Sensitivity HRAM
More informationBiotherapeutic Method Development Guide
Biotherapeutic Method Development Guide HALO BIOCLASS 1000 Å PROTEIN SELECTIVITY KIT Fused-Core Particle Technology BIOCLASS Strategy for Optimizing Protein Separations Using Reversed-phase Liquid Chromatography
More informationBioConfirm B Presentation
BioConfirm B.08.00 Presentation 1 Major Enhancements to Increase Your Productivity The Latest Version of our BioConfirm Product, B.08.00 BioConfirm is protein and peptide characterization software using
More informationApplication Note. Authors. Abstract. Ravindra Gudihal Agilent Technologies India Pvt. Ltd. Bangalore India
Characterization of bacteriophage derived anti-staphylococcal protein (P28) from production to purification using Agilent HPLC-Chip Q-TOF LC/MS system Application Note Authors Ravindra Gudihal Agilent
More informationMAbPac RP Column. High-performance reverse phase chromatography column for monoclonal antibody analysis
CHROMATOGRAPHY MAbPac RP Column High-performance reverse phase chromatography column for monoclonal antibody analysis Product Specifications The Thermo Scientific MAbPac RP is a reverse phase (RP) liquid
More informationHongwei Xie, Martin Gilar, and John C. Gebler Waters Corporation, Milford, MA, U.S.A. INTRODUCTION EXPERIMENTAL
Analysis of Deamidation and Oxidation in MONOCLONAL Antibody Using Peptide Mapping with UPLC/MS E Hongwei Xie, Martin Gilar, and John C. Gebler Waters Corporation, Milford, MA, U.S.A. INTRODUCTION Monoclonal
More informationFast Online Desalting of mabs Using a Reversed-Phase Desalting Cartridge for LC-MS Analysis
Fast Online Desalting of mabs Using a Reversed-Phase Desalting Cartridge for LC-MS Analysis Martin Samonig,¹ Shane Bechler,² Kelly Flook², and Remco Swart¹ ¹Thermo Fisher Scientific, Germering, Germany
More informationRapid Soft Spot Analysis using the SCIEX Routine Biotransform Solution
Rapid Soft Spot Analysis using the SCIEX Routine Biotransform Solution Rapidly Identify Top Metabolites with the SCIEX X500R QTOF System and MetabolitePilot TM 2.0 Software Shaokun Pang and Ian Moore SCIEX,
More informationQuantification of Host Cell Protein Impurities Using the Agilent 1290 Infinity II LC Coupled with the 6495B Triple Quadrupole LC/MS System
Application Note Biotherapeutics Quantification of Host Cell Protein Impurities Using the Agilent 9 Infinity II LC Coupled with the 6495B Triple Quadrupole LC/MS System Authors Linfeng Wu and Yanan Yang
More informationTurboMass GC/MS Software
TurboMass GC/MS Software GAS CHROMATOGRAPHY / MASS SPECTROMETRY P R O D U C T N O T E Today s demanding laboratory requires software that is easy to learn yet offers sophisticated instrument control, robust
More informationBiotherapeutic Method Development Guide
Biotherapeutic Method Development Guide HALO BIOCLASS 1000 Å PROTEIN SELECTIVITY KIT Fused-Core Particle Technology BIOCLASS Strategy for Optimizing Protein Separations Using Reversed-phase Liquid Chromatography
More informationChromatographic Workflows for Biopharmaceutical Characterization
Chromatographic Workflows for Biopharmaceutical Characterization Dr. Ken Cook European Bioseparation Sales Support Expert Thermo Fisher Scientific, Hemel Hempstead/Germany The world leader in serving science
More information基于质谱的蛋白质药物定性定量分析技术及应用
基于质谱的蛋白质药物定性定量分析技术及应用 蛋白质组学质谱数据分析 单抗全蛋白测序及鉴定 Bioinformatics Solutions Inc. Waterloo, ON, Canada 上海 中国 2017 1 3 PEAKS Studio GUI Introduction Overview of PEAKS Studio GUI Project View Tasks, running info,
More informationTargeted and Untargeted Screening of Microcystins in Lake Water Samples Using High Resolution Mass Spectrometry INTRODUCTION
Targeted and Untargeted Screening of Microcystins in Lake Water Samples Using High Resolution Mass Spectrometry Lauren Mullin, 1 Xavier Ortiz Almirall, 2 Stuart Oehrle, 1 and Adam Ladak 1 1 Waters Corporation,
More informationExpand Your Research with Metabolomics and Proteomics. Christine Miller Omics Market Manager ASMS 2017
Expand Your Research with Metabolomics and Proteomics Christine Miller Omics Market Manager ASMS 2017 New Additions to Agilent Omics Workflows Acquisition Ion Mobility Q-TOF IM All Ions MS/MS Find Features
More informationThe Overview of LC-MS Quantitative Solutions for Biotherapeutic Analysis
The Overview of LC-MS Quantitative Solutions for Biotherapeutic Analysis Featuring SCIEX Instrumentation and Technologies Lei Xiong, Elliott Jones SCIEX, Redwood City, California, USA Figure 1. Summary
More informationPeptide Mapping of Glycoprotein Erythropoietin by HILIC LC/MS and RP-LC/MS
Peptide Mapping of Glycoprotein Erythropoietin by HILIC LC/MS and RP-LC/MS Application Note BioPharma Authors Alex Zhu, James Martosella, and Phu T Duong Agilent Technologies, Inc Introduction Peptide
More informationA Comprehensive Workflow to Optimize and Execute Protein Aggregate Studies
A Comprehensive Workflow to Optimize and Execute Protein Aggregate Studies Combining Size Exclusion Chromatography with Method Development and Light Scattering Application Note Biotherapeutics and Biosimilars
More informationACQUITY UPLC H-Class Bio System
QUITY UPL H-lass io System uilt for your biomolecular characterization t he IocoM Pt Ile u P lc P lt FoRM The QUITY UPL H-lass io System the latest extension to the family of QUITY UPL Systems, brings
More informationNISTmAb characterization with a high-performance RP chromatography column
APPLICATION NOTE 21848 NISTmAb characterization with a high-performance RP chromatography column Author Xin Zhang Thermo Fisher Scientific, Sunnyvale, CA, USA Keywords MAbPac RP column, inter-column reproducibility,
More informationrapiflex Innovation with Integrity Designed for Molecules that Matter. MALDI TOF/TOF
rapiflex Designed for Molecules that Matter. Innovation with Integrity MALDI TOF/TOF rapiflex TM The first MALDI-TOF/TOF that adapts to your needs. The rapiflex is the most advanced MALDI TOF/TOF system
More informationAssessment of Active Biopharmaceutical Ingredients Prior To and Following Removal of Interfering Excipients
Assessment of Active Biopharmaceutical Ingredients Prior To and Following Removal of Interfering Excipients Andrew J Reason and Howard R Morris BioPharmaSpec Ltd, and BioPharmaSpec Inc, The EMA guideline
More informationZipChipTM. Microfluidic CE-ESI Chip Separations Biotherapeutics. March // Actionable Intelligence HPMS & On-board Analytics / Slide 1
ZipChipTM Microfluidic CE-ESI Chip Separations Biotherapeutics March 2016 // Actionable Intelligence HPMS & On-board Analytics / Slide 1 March 2016 //ZipChip Biotherapeutics Analysis Summary Fast, high-resolution
More informationDETERMINATION OF PROTEIN BINDING BY UPLC/MS/MS
DETERMINATION OF PROTEIN BINDING BY UPLC/MS/MS Darcy Shave and Pete Alden Waters Corporation, Milford, MA, U.S.A. INTRODUCTION Plasma protein binding (PPB) can significantly affect the therapeutic action
More information